日米における適応的デザインを用いた臨床試験の現状

Translated title of the contribution: Application of adaptive designs in clinical trials in Japan and the United States

Naoto Yamakawa, Satoshi Teramukai, Tomohiro Hatta, Hisashi Urushihara

Research output: Contribution to journalArticle

Abstract

Clinical trials using adaptive designs(AD)are more flexible in study design and implementation compared to conventional fixed designs. In the US, the draft guidance documentËAdaptive Design Clinical Trials for Drugs and BiologicsÌwas issued by the FDA in 2010, and many studies using AD have been performed. On the other hand, the situation of practical application of AD to clinical trials in Japan has not been reported and no guidance has been issued. We investigated the use of AD in both Japan and the US by searching public clinical trial registration databases in both countries. Four databases were used for searching clinical trials carried out in Japan, and one database for the US. We included clinical trials using AD registered between January 1, 2013 and December 31, 2017. Twenty-four AD trials conducted in Japan and 97 conducted in the US were identified. The AD were used mainly in the early phase of clinical development. Of the 24 trials conducted in Japan, 23 were sponsored by pharmaceutical companies. In particular, AD were frequently used in clinical trials led by global pharmaceutical companies and overseas affiliate of Japanese companies. In the US, the numbers of domestic AD trials and multinational AD trials were almost the same, and some of them were led by academic institutions. These findings suggest that Japanese companies have limited experience in using AD, and that AD are not yet popular in Japan. Efforts to enhance understanding of AD, such as issuing guidance by regulatory authorities in Japan, are needed to promote diffusion of efficient clinical development using AD.

Original languageJapanese
Pages (from-to)149-156
Number of pages8
JournalJapanese Journal of Clinical Pharmacology and Therapeutics
Volume50
Issue number4
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Japan
Clinical Trials
Databases
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

日米における適応的デザインを用いた臨床試験の現状. / Yamakawa, Naoto; Teramukai, Satoshi; Hatta, Tomohiro; Urushihara, Hisashi.

In: Japanese Journal of Clinical Pharmacology and Therapeutics, Vol. 50, No. 4, 01.01.2019, p. 149-156.

Research output: Contribution to journalArticle

@article{4e1930cc3dc0459c8bc8ab31d282c419,
title = "日米における適応的デザインを用いた臨床試験の現状",
abstract = "Clinical trials using adaptive designs(AD)are more flexible in study design and implementation compared to conventional fixed designs. In the US, the draft guidance document{\"E}Adaptive Design Clinical Trials for Drugs and Biologics{\`I}was issued by the FDA in 2010, and many studies using AD have been performed. On the other hand, the situation of practical application of AD to clinical trials in Japan has not been reported and no guidance has been issued. We investigated the use of AD in both Japan and the US by searching public clinical trial registration databases in both countries. Four databases were used for searching clinical trials carried out in Japan, and one database for the US. We included clinical trials using AD registered between January 1, 2013 and December 31, 2017. Twenty-four AD trials conducted in Japan and 97 conducted in the US were identified. The AD were used mainly in the early phase of clinical development. Of the 24 trials conducted in Japan, 23 were sponsored by pharmaceutical companies. In particular, AD were frequently used in clinical trials led by global pharmaceutical companies and overseas affiliate of Japanese companies. In the US, the numbers of domestic AD trials and multinational AD trials were almost the same, and some of them were led by academic institutions. These findings suggest that Japanese companies have limited experience in using AD, and that AD are not yet popular in Japan. Efforts to enhance understanding of AD, such as issuing guidance by regulatory authorities in Japan, are needed to promote diffusion of efficient clinical development using AD.",
keywords = "Adaptive design, clinical trials",
author = "Naoto Yamakawa and Satoshi Teramukai and Tomohiro Hatta and Hisashi Urushihara",
year = "2019",
month = "1",
day = "1",
doi = "10.3999/jscpt.50.149",
language = "Japanese",
volume = "50",
pages = "149--156",
journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",
issn = "0388-1601",
publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",
number = "4",

}

TY - JOUR

T1 - 日米における適応的デザインを用いた臨床試験の現状

AU - Yamakawa, Naoto

AU - Teramukai, Satoshi

AU - Hatta, Tomohiro

AU - Urushihara, Hisashi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Clinical trials using adaptive designs(AD)are more flexible in study design and implementation compared to conventional fixed designs. In the US, the draft guidance documentËAdaptive Design Clinical Trials for Drugs and BiologicsÌwas issued by the FDA in 2010, and many studies using AD have been performed. On the other hand, the situation of practical application of AD to clinical trials in Japan has not been reported and no guidance has been issued. We investigated the use of AD in both Japan and the US by searching public clinical trial registration databases in both countries. Four databases were used for searching clinical trials carried out in Japan, and one database for the US. We included clinical trials using AD registered between January 1, 2013 and December 31, 2017. Twenty-four AD trials conducted in Japan and 97 conducted in the US were identified. The AD were used mainly in the early phase of clinical development. Of the 24 trials conducted in Japan, 23 were sponsored by pharmaceutical companies. In particular, AD were frequently used in clinical trials led by global pharmaceutical companies and overseas affiliate of Japanese companies. In the US, the numbers of domestic AD trials and multinational AD trials were almost the same, and some of them were led by academic institutions. These findings suggest that Japanese companies have limited experience in using AD, and that AD are not yet popular in Japan. Efforts to enhance understanding of AD, such as issuing guidance by regulatory authorities in Japan, are needed to promote diffusion of efficient clinical development using AD.

AB - Clinical trials using adaptive designs(AD)are more flexible in study design and implementation compared to conventional fixed designs. In the US, the draft guidance documentËAdaptive Design Clinical Trials for Drugs and BiologicsÌwas issued by the FDA in 2010, and many studies using AD have been performed. On the other hand, the situation of practical application of AD to clinical trials in Japan has not been reported and no guidance has been issued. We investigated the use of AD in both Japan and the US by searching public clinical trial registration databases in both countries. Four databases were used for searching clinical trials carried out in Japan, and one database for the US. We included clinical trials using AD registered between January 1, 2013 and December 31, 2017. Twenty-four AD trials conducted in Japan and 97 conducted in the US were identified. The AD were used mainly in the early phase of clinical development. Of the 24 trials conducted in Japan, 23 were sponsored by pharmaceutical companies. In particular, AD were frequently used in clinical trials led by global pharmaceutical companies and overseas affiliate of Japanese companies. In the US, the numbers of domestic AD trials and multinational AD trials were almost the same, and some of them were led by academic institutions. These findings suggest that Japanese companies have limited experience in using AD, and that AD are not yet popular in Japan. Efforts to enhance understanding of AD, such as issuing guidance by regulatory authorities in Japan, are needed to promote diffusion of efficient clinical development using AD.

KW - Adaptive design, clinical trials

UR - http://www.scopus.com/inward/record.url?scp=85072946821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072946821&partnerID=8YFLogxK

U2 - 10.3999/jscpt.50.149

DO - 10.3999/jscpt.50.149

M3 - Article

AN - SCOPUS:85072946821

VL - 50

SP - 149

EP - 156

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

SN - 0388-1601

IS - 4

ER -